Additional Information

Description

Xolair (omalizumab) 150 mg is a monoclonal antibody used for the treatment of moderate to severe persistent asthma and chronic urticaria (hives) in patients who have not responded adequately to other therapies. It works by binding to and inhibiting immunoglobulin E (IgE), a key mediator in allergic responses. By reducing IgE levels, Xolair helps prevent the release of inflammatory substances in the body, thus reducing allergic symptoms such as wheezing and hives.

In asthma management, Xolair is used as an adjunctive treatment to control symptoms when inhaled corticosteroids and other asthma medications do not provide adequate relief. In chronic urticaria, it is prescribed to control symptoms in patients who do not respond to antihistamines.

Common side effects include headache, injection site reactions, and upper respiratory infections. Serious side effects may include anaphylaxis, cardiovascular issues, and malignancies. It is important for patients to undergo regular monitoring while using Xolair to check for potential complications.